Media 280723

CTO Mr Craig Weller said on Aqua Phase studies revealing the absorption of CBD as more than 4 times greater than CBD in oil:
Bod has been sweating on the PK study for months. It needed to show improved bioavailability of 30% for the deal to proceed, it exceeded by a factor of 10, what this means is that if we ingest 100mg of CBD in oil, we will normally absorb 6-8% of the dose. With Aqua Phase, the CBD absorption is 32% This means we can either get a better response to the CBD or otherwise we can reduce the Aqua Phase dose – giving potentially less side effects and providing CBD raw material savings.
Bod Science (ASX:BOD) expands cannabis products into Malaysian market
21 Jun 2023
Published by: The Market Herald
Bod eyes Malaysian market in tie-up with Antah Group
21 Jun 2023
Published by: Cannabiz
ASX Health Stocks: BOD to sell cannabis in Malaysia; AHI explores the burgeoning Middle East e-script market
21 Jun 2023
Published by: Stockhead
Bod Science to test drug-delivery tech on psychiatric medication
31 May 2023
Published by: Cannabiz
Hopes rising at Bod Science over commercial prospects for Aqua Phase
23 May 2023
Published by: Cannabiz
BOD: Phase IIb CBD-insomnia trial recruitment complete
04 Apr 2023
Published by: Next Investors
BOD: Clinical trials set to begin on chemist-available, cannabis insomnia treatment
24 Mar 2023
Published by: Next Investors
Bod CEO ‘confident’ firm will register over-the-counter CBD medicine as insomnia trial progresses
14 Mar 2023
Published by: Cannabiz